Bladder Cancer

BLADDER CANCER NEWS TIPS & FEATURES

Keytruda Immunotherapy Improves Overall Survival in Bladder Cancer

November 10th, 2016

Keytruda Immunotherapy Improves Overall Survival in Bladder Cancer

Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average age that patients are diagnosed with bladder […]


Tecentriq® Approved for Bladder Cancer

June 8th, 2016

Tecentriq® Approved for Bladder Cancer

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to […]


Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer

June 8th, 2016

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate […]


Ask the Lynch Syndrome Expert Q&A Now Available

June 2nd, 2016

Ask the Lynch Syndrome Expert Q&A Now Available

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity […]


Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who […]


Durvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients with PD-L1 Positive Urothelial Bladder Cancer

February 19th, 2016

Durvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients with PD-L1 Positive Urothelial Bladder Cancer

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death […]


Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer

January 21st, 2016

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were […]


Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer

March 31st, 2015

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These […]


Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer

March 30th, 2015

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. […]


Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

March 16th, 2015

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous […]


More News →